Brief: Biomea Fusion Announces Preliminary Data From Ongoing Covalent-103 Study Of Investigational Covalent Flt3 Inhibitor Bmf-500 In Relapsed Or Refractory Acute Leukemia
09/12/2024 21:02
Dec 10 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES PRELIMINARY DATA FROM ONGOING
COVALENT-103 STUDY OF INVESTIGATIONAL COVALENT FLT3 INHIBITOR
BMF-500 IN RELAPSED OR REFRACTORY ACUTE LEUKEMIA
* BIOMEA FUSION INC - BMF-500 SHOWS FAVORABLE SAFETY PROFILE
WITH
NO DOSE-LIMITING TOXICITIES
* BIOMEA FUSION INC - PRELIMINARY DATA SUPPORTS BMF-500 AS
TRANSFORMATIVE THERAPY FOR FLT3 MUTATED R/R ACUTE LEUKEMIA
Source text: urn:newsml:reuters.com:*:nGNX3rq5pv
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes